PREPARATION OF 99mTc-TRICINE-EDDA-HYNIC-FOLATE, A POTENTIAL RADIOPHARMACEUTICAL FOR RADIODIAGNOSIS OF FOLATE RECEPTORS OVER EXPRESSED CANCER by Ramli, Martalena et al.
51
Preparation of 99mTc-tricine-EDDA-HYNIC-Folate, A Potential Radiopharmaceutical for Radiodiagnosis of Folate receptors
Positive Cancer (Martalena Ramli)
Akreditasi LIPI No.: 395/D/2012
Tanggal 24 April 2012
ISSN: 1411-1098
Homepage: http://jusami.batan.go.id
Jurnal Sains Materi Indonesia
PREPARATION OF 99mTc-TRICINE-EDDA-HYNIC-FOLATE,
A POTENTIAL RADIOPHARMACEUTICAL FOR
RADIODIAGNOSIS OF FOLATE RECEPTORS
OVER EXPRESSED CANCERS
Martalena Ramli, Rien Ritawidya, Cecep Taufik Rustendi,
Titis Sekar Humani and Widyastuti Widjaksana
Radioisotope and Radiopharmaceutical Technological Centre (PRR)-BATAN
Kawasan Puspiptek, Serpong 15314, Tangerang Selatan
E-mail: marta_r@batan.go.id
Diterima: 03 Mei 2013 Diperiksa: 26 Agustus 2013 Disetujui: 19 September 2013
ABSTRACT
PREPARATION OF 99mTc-TRICINE-EDDA-HYNIC-FOLATE, A POTENTIAL
RADIOPHARMACEUTICAL FOR RADIODIAGNOSIS OF FOLATE RECEPTORS OVER
EXPRESSED CANCER. Folate receptors (FRs) have been reported to be over expressed on various types
of cancers. Therefore, it would be possible for its ligand in this case folic acid, also known as vitamin B9,
to be used as delivery agent for diagnosis and therapy of FRs over expressed cancers. The aim of this
project was to prepare 99mTc radiolabeled folic acid via 6-hydrazinonicotinamido-hydrazido (HYNIC) in the
form of 99mTc-tricine-ethylenediamine diacetate-HYNIC-folate (99mTc-tricine-EDDA-HYNIC-folate),
which was expected to be potential for radiodiagnosis of the FRs over expressed cancers. Preparation
of 99mTc-tricine-EDDA-HYNIC-folate was initiated by preparation of HYNIC-folate by reacting of  folate-γ-
hydrazide with 6-chloronicotinic acid NHS ester which was then followed by addition of hydrazine-hydrate.
The HYNIC-folate was recovered in its HCl salt-form which was then formulated to form a freeze dried kit
which consisted of HYNIC-folate, tricine and EDDA (co-ligands) and Sn(II) as reducing agent. The formation
of 99mTc-tricine-EDDA-HYNIC-folate was carried out by addition of 99mTc into tricine-EDDA-HYNIC-folate
freeze dried kit which resulted in 99mTc-tricine-EDDA-HYNIC-folate with radiochemical purity of
97.0 ± 1.8% met with the requirement of a good radiopharmaceutical ( 90%). The stability test showed that
the 99mTc-tricine-EDDA-HYNIC-folate was still intact (radiochemical purity ~ 95%) when stored at 37 C for
four hours.
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ABSTRAK
PREPARASI 99mTc-TRICINE-EDDA-HYNIC-FOLATE, RADIOFARMAKAPOTENSIALUNTUK
RADIODIAGNOSIS KANKER OVER EXPRESSED RESEPTOR FOLAT. Reseptor Folat (FRs) dilaporkan
over expressed pada beberapa jenis kanker. Asam folat atau yang juga dikenal sebagai vitamin B9 merupakan
ligan dari FRs, sehingga asam folat memungkinkan untuk digunakan sebagai pembawa radionuklida untuk
radiodiagnosis atau radioterapi kanker over expressed FRs. Tujuan penelitian ini adalah untuk menyiapkan
asam folat bertanda 99mTc dengan menggunakan 6-hydrazinonicotinamido-hydrazido (HYNIC) sebagai bifunctional
chelating agent dalam bentuk 99mTc-tricine-ethylenediamine diacetate-HYNIC-folate (99mTc-tricine-EDDA-HYNIC-
folate) yang diharapkan potensial untuk radiodiagnosis kanker over expressed FRs. Preparasi 99mTc-tricine-
EDDA-HYNIC-folate diawali dengan penyiapan HYNIC-folate dengan mereaksikan folate-γ-hydrazide dengan
6-chloronicotinic acid NHS ester yang diikuti dengan penambahan hydrazine-hydrate. HYNIC-folate yang
terbentuk kemudian diisolasi dalam bentuk garam HYNIC-folate-HCl yang kemudian diformulasi dalam bentuk
freeze dried kit yang mengandung HYNIC-folate, tricine dan EDDA (co-ligands) serta Sn(II) sebagai reduktor.
Penyiapan 99mTc-tricine-EDDA-HYNIC-folate dilakukan dengan menambahkan 99mTc pada freeze dried kit tricine-
EDDA-HYNIC-folate yang menghasilkan 99mTc-tricine-EDDA-HYNIC-folate dengan kemurnian radiokimia 97,0
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INTRODUCTION
Cancer has now become one of health problems
around the world. Based on Globocan report in 2012
there were 14.090 millions of new cancer cases with
number of deaths of 8.201 millions out of 7.054446 billions
total world population. Five most frequent for the
above-mentioned cancers were lung, breast, colorectal,
prostate and stomach cancers. In case of Indonesia,
in 2012 Globocan reported there were around
299.7 thousands of new cancer with a number of deaths
of around 194.5 thousands out of around 245 millions of
population. Five most frequent for the above-mentioned
cancers were breast, lung, colorectal, cervix uteri stomach
and liver cancers [1]. These statistics show that cancer
has become a heavy burden to our society welfare
physically and emotionally.
Radiopharmaceutical is one of many modalities
that have been used in cancer management. It can be
used as radiodiagnostic or radioimaging and/or
radiotherapeutic agents. In recent years there has been
a tendency to use targeted radiopharmaceuticals in order
to avoid unnecessary radiation to normal cells. This
can be performed by exploiting a phenomenon of an
affinity between target on surface of cancer cells and its
associated ligand. There are several targets that can be
exploited for the above mentioned purposes. Some of
them are CD20, CD30, CD52, epidermal growth factor
receptor (EGFR), vascular endothelial growth factor
(VEGF), human epidermal receptor type 2 (HER-2)
and folate receptors (FRs) [2,3]. Suitable ligands for
the above-mentioned targets could be biomolecules
such as monoclonal antibodies, peptides, hormones,
vitamins and other biomolecules. For a targeted
radiopharmaceuticals these ligands are used to deliver
the conjugated or attached probe in form of
radionuclides which emits a  gamma radiation and/or
 or  particles.
Folic acid, which is also known as vitamin B9 and
has a molecular weight of 441 Da, is an essential vitamin
required for proliferation and maintenance of mammalian
cells [4-6]. Folic acid is internalised by normal mammalian
cells via either a low affinity reduced folate carrier (RFC)
or proton-coupled folate transporter (PCFT). Unlike
folate, conjugated folate does not show any affinity
toward RFC or PCFT. However, conjugated folates do
have high affinity (Kd: 10
-10 M) toward folate receptors
(FRs) which are over expressed and accessible on several
cancers such as ovary, lung, breast, kidney, brain,
endometrial, colon and hematopoietic cells of
myelogenous origin, also on activated macrophages and
proximal tubule cells of the kidney. Therefore, folate
based radiopharmaceuticals are expected to be versatile
and target specific for diagnosis and/ or therapy of FRs
over expressed cancers.
There have been several investigations related
to the use of folate based radiopharmaceutical for
radiodiagnostic agents. These include 111In diethylene-
triamine pentaacetic acid (DTPA)-folate and 99mTc
6-hydrazinonicotinamido-hydrazido (99mTc-HYNIC)-
folate with co-ligands of tricine and trisodium
triphenylphosphine-3,3,3’’-trisulfonate (TPPTS) [7-9].
Pre-clinical and clinical tests showed that these agents
were potential for imaging of FRs over expressed positive
cancers.
However, there have been a few drawbacks in
the use of the above-mention agents. These included
the use of 111In which was considered less suitable for
radiodiagnostic agent due to its Auger and Coster
Kronig electrons and preparation of radiolabeling DTPA-
folate with 111In which involved two-step reaction where
111In first has to be complexed with citrate. The resulted
111In-citrate was then reacted with DTPA-folate to form
111In- DTPA-folate [7,10]. In case of 99mTc-tricine-TSPP-
HYNIC-folate, radiolabeling of tricine-TSPP-HYNIC-
folate with 99mTc can be performed in one step reaction
which is much preferred by the users [9]. However,
production of 99mTc-tricine-TPPTS-HYNIC-folate which
has a great potential for radiodiagnostic agent of FRs
over expressed cancers has been threatened due the
the difficulty in procurement of its co-ligands TPPTS.
The purpose of this study was therefore to
prepare 99mTc-HYNIC with co-ligand such as tricine-
ethylendiaminediaceticacid (EDDA) which can procured
easily and expected to provide a stable 99mTc-HYNIC-
folate with acceptable radiochemical purity (> 90%).
EXPERIMENTALMETHOD
Material and Equipment
Chemicals and materials used in this
project included folate-γ-hydrazide provided by
Chiroblock (Germany), dicyclocarbodiimide (DCC),
N-hydrosuccinimide (NHS), dimethylsulfoxide
(DMSO) and hydrazine hydrate, tricine, and
ethylendiaminediacetic acid (EDDA) were obtained
from Aldrich Chemical. Tc-99m was generated from
99Mo/99mTc Generator (PT. BATAN Teknologi,
Indonesia). Silica gel impregnated glass fibre sheets/
± 1,8% yang memenuhi persyaratan kemurnian radiokimia suatu radiofarmaka yang baik ( 90%). Hasil uji
stabilitas 99mTc-tricine-EDDA-HYNIC-folate memperlihatkan bahwa radiofarmaka ini masih tetap utuh (kemurnian
radiokimia ~ 95%) setelah disimpan pada 37 C selama 4 jam.
Kata kunci: Reseptor folat, Kanker, Radiofarmaka diagnosis, 99mTc-tricine-EDDA-HYNIC-folate
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instance thin layer chromatography-silica gel
(ITLC-SG) were obtained from Pall.
Equipment used in this research included
magnetic stirrer (Cimarec), centrifuge (Hettich-EBA 8S),
FT-IR Spectrometer (Jasco-410), thin layer
chromatographic scanner (Bio Scan), dose calibrator
(Capintec - CRC-15R) and thermomixer (Bio Rad).
Synthesis of 6-Hydrazinonicotinamido-
Hydrazido (HYNIC)-Folate (5)
The synthesis scheme of HYNIC-folate is shown
in Figure 1. This synthesis procedure is performed in
similar manner to that of Guo et al [9]. HYNIC-folate was
prepared by reacting folate-γ-hydrazide (1) with
6-chloronicotinic acid NHS-ester (3). 6-Chloronicotinic
acid NHS-ester (3) was prepared by dissolving
6-chloronicotinic acid (1) (200 mg) in 2 mL DMSO which
was followed by addition of NHS (2) (146 mg) and DCC
(261 mg) (Figure 2). The reaction mixture was left to
react for four hours at ambient temperature with stirring
and protected from light. Dicyclohexylurea, by product,
was removed by a pellet formation using a centrifuge.
After pellet removal, one mL of reaction mixture was
withdrawn and then added to folate-γ-hydrazide (50 mg)
in 2 mL of DMSO. Reaction mixture was left to react for
four hours at ambient temperature with stirring to form
folate-6-chloronicotinamide (4) which was then followed
by addition of hydrazine-hydrate (200 mg). The reaction
mixture was left to react overnight which was followed
by addition of 100 μL of 0.5 N HCl to produce HYNIC-
folate.HCl. The salt was then separated by centrifugation
which was then recovered and washed with ethanol
(4 times). Finally, the salt was washed with ether and left
to dry under vacuum at - 20o C. The product was then
analysed by a FT-IR Spectrometer.
Formulation of Tricine-EDDA-HYNIC-Folate
Cold Kit
Tricine-EDDA-HYNIC-folate freeze dried kit was
prepared by adding 800 μL of HYNIC-folate solution
(0.5 mg/ mL) in 0.1 M phosphate buffer pH 6 into a mixture
of tricine (100 mg) and EDDA (200 mg) in 500 µL H2O.
Aliquot (500 µL) of SnCl2.2H2O (1 mg/mL) in N2-saturated
H2O was then added which was followed by pH
adjustment to 7 with addition of 1N NaOH. The solution
diluted with H2O to give a final volume of 10 mL. The
solution was then flushed with N2for five minutes which
was then followed by dispensing to a series of 10 mL
vials (1 mL/vial) and freeze drying for 24 hours.
Radiolabeling of Tricine-EDDA-HYNIC-
Folate with 99mTc
Radiolabeling tricine-EDDA-HYNIC-folate with
99mTc was performed by firstly reconsituting the tricine-
EDDA-HYNIC-folate freeze dried kit with one mL of
0.1 M phosphate buffer pH 7. Tc-99m (5 – 10 mCi) which
was generated from 99Mo/99mTc-Generator was added
and the reaction mixture was heated at 80 oC for
30 minutes. Radiochemical purity of 99mTc-tricine-EDDA
HYNIC-folate was then determined by two thin layer
chromatographic (TLC) systems using ITLS-SG as a
stationary phase with acetone and saline solution (0.9%
NaCl) as mobile phases.
Determination of Radiochemical Purity of
99mTc-Tricine-EDDA-HYNIC-Folate
Radiochemical purity of 99mTc-tricine-EDDA
HYNIC-folate was determined by two TLC systems: a)
ITLS-SG as a stationary phase and acetone as mobile
phase; and b) ITLS-SG as a stationary phase and saline
solution (0.9% NaCl) as mobile phase. ITLC-SG sheets
were cut into strips (0.8 x 10 cm). The strips were activated
by heating at 110 oC for at least 10 minutes before their
use. Aliquot of the reaction mixture was spotted 1 cm
from the bottom of four ITLC-SG strips. Two ITLC-SG
strips were developed in acetone and the other two were
in saline solution (0.9% NaCl). When the solvent front
was within 0.5 cm of the top of the strips, they were then
Figure 1. Preparation scheme of HYNIC-folate [9]
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removed and allowed to dry on blotting paper. The strips
were then scanned by TLC scanner. The percentage of
complex 99mTc-tricine-EDDA-HYNIC-folate was
calculated by deducting the percentage of radioactivity
which was associated with 99mTc-tricine-EDDA-HYNIC-
folate with the percentage of radioactivity which was
associated with free 99mTc and 99mTcO2.
Determination of Stability of 99mTc-Tricine-
EDDA HYNIC-Folate
99mTc- tricine-EDDA-HYNIC-folate was stored at
37 oC for up to four hours. Aliquots were removed at
one, two, three and four hours and then analysed for
their radiochemical purity by two TLC systems : a). ITLC-
SG as a stationary phase and acetone as mobile phase;
and b). ITLC-SG as a stationary phase and saline solution
(0.9% NaCl) as mobile phase.
RESULTS AND DISCUSSIONS
HYNIC-folate (5) was prepared by reacting folate
-hydrazide (1) with 6-chloronicotinic acid NHS ester
(3) (Figure 1) where 6-chloronicotinic acid NHS ester (3)
was prepared by reacting 6-chloronicotinic acid (1) with
NHS (2) in the presence of DCC (Figure 2).
Figure 3(a) and 3(b) show the FT-IR spectrum of
the formed HYNIC-folate and folate -hydrazide
(precursor) respectively. The formation of HYNIC-folate
could be recognised by absorbance on the 900-675 cm-1
region (Figure 3(a)). This region is the most characteristic
absorbance for polynuclear aromatics which are
generated from C-H out of plane bending [11]. It can be
seen in Figure 3(a), there are three strong bands on the
region between 900 - 675 cm-1 that correlate with the
number of adjacent hydrogen atom on the rings. For
comparison, on Figure 3(b) (FT-IR spectrum of folate
-hydrazide) there are relative weak bands on the
900 - 675 cm-1 region. These indicated that there
were less hydrogen atom on the rings on the latter
(folate -hydrazide) compared to that of the former
(HYNIC-folate).
HYNIC was firstly introduced by Abrams, et al.
[12] as bifunctional chelating agent (BFCA) or ligand
for tagging a biomolecule (BM) with 99mTc and acts as a
monodentate ligand. Therefore, when it is used for
chelating 99mTc (which is able to receive seven pairs of
lone electrons), it has to be accompanied by co-ligand
in order to stabilize the resulting 99mTc-HYNIC complex.
There were several reports related to the use of HYNIC
as BFCAfor radiolabeling of BM with 99mTc where tricine,
TSPP, or EDDAuses as co-ligand/s [9,13,14]. Preparation
of 99mTc-HYNIC-BM where tricine used as co-ligand has
been reported to be relatively simple. It could be
performed at room temperature (20 C) with reaction time
of 10 minutes which resulted in 99mTc-tricine-HYNIC-BM
with radiochemical purity > 99% [14]. The resulted
99mTc-tricine-HYNIC-BM complex however was reported
to be unstable and also presence in multiple species in
solution due to different bonding modalities of HYNIC
and co-ligands. On the other hand, radiolabeling of
HYNIC-BM such as HYNIC-folate and HYNIC-
Duramycin with 99mTc where tricine along with TPPTS
used as co-ligand resulted in stable 99mTc-tricine-TPPTS-
HYNIC-folate and 99mTc-tricine-TPPTS-HYNIC-
Duramycin complexes respectively [9,13]. The
radiolabeling procedure for the above-mentioned
HYNIC-BM was relatively simple and gave radiochemical
purity > 90%. However, the difficulty in procurement of
TPPTS has leaded to the use of other co-ligand for
radiolabeling HYNIC-BM with 99mTc.
EDDA is one of co-ligands that has ben explored
for radiolabeling of HYNIC-BM [15,16]. Radiolabeling
HYNIC-folate with 99mTc with co-ligand EDDA which
was carried out in our laboratory however, only resulted
in 99mTc-EDDA-HYNIC-folate with an average
radiochemical purity of 75% which is not met with the
radiochemical purity of a good radiopharmaceutical (>
90%) [17]. This result was in agreement with report on
radiolabeling of HYNIC-BM with 99mTc where EDDAused
as a sole co-ligand [15]. This procedure is not preferred
by users as 99mTc-EDDA-HYNIC-folate had to be purified
to increase its radiochemical purity (> 90%) prior its use.
Nevertheless, purified 99mTc-EDDA-HYNIC-folate
reported to be more stable compared to 99mTc-tricine-
HYNIC-folate. Referring to the simple procedure for
radiolabeling HYNIC-BM with 99mTc where tricine and
TSPP used as co-ligand, it was then a new approach for
radiolabeling of HYNIC-BM with 99mTc being developed.
In this work, radiolabeling of HYNIC-folate with
99mTc was peformed by using tricine along with EDDA
(a)
(b)
Figure 3. FT-IR spectrum of HYNIC folate (a) and folate
g-hydrazide (b)
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as co-ligands. Freeze dried kits, which contained HYNIC-
folate, tricine, EDDA and certain amount of Sn(II) that
required for reducing of Tc(VII) to Tc(V), were prepared.
Radiolabeling of the above-mentioned kit was carried
out by firstly reconstituting the freeze dried kit with
0.1 M phosphate buffer pH 7 which was then followed
by adition of 99mTc (5 – 10 mCi). Reaction mixture was
left to react at 80 oC for 30 minutes before aliquots were
taken for radiochemical purity test by using two TLC
systems.
Based on the ITLC-SG–acetone system
(Figure 5(a)) the 99mTc-tricine-EDDA-HYNIC-folateand
99mTcO2 would have an Rf < 0.5 and the free
99mTcO4
-
would have an Rf >0.5. The 99mTcO2 colloid that
might be produced in radiolabeling process due to
an excess of Sn(II) was measured by using ITLC-SG-
saline system. Based on this TLC, the colloidal
99mTcO2 would have an Rf < 0.5 while the
99mTc- tricine-
EDDA-HYNIC-folate and free 99mTcO4
- would have
an Rf > 0.5 (Figure 5(b)). It can be seen on Figure 5(a)
that there was 97.26% of the 99mTc- tricine-EDDA-HYNIC-
folate and 2.74% 99mTcO2 after radiolabeling process.
From Figure 5(b) it can be seen that the percentage
of 99mTcO2 in the
99mTc-tricine-EDDA-HYNIC-folate
product was of 2.06%. The tabulated of RFs of each
component resulted from radiolabeling of the 99mTc-
tricine-EDDA-HYNIC-folate with 99mTc determined with
two TLC systems is shown in Table 1.
The percentage of 99mTc-tricine-EDDA-HYNIC-
folate formed, expressed as radiochemical purity,
calculated by deducting the percentage of radioactivity
which was associated with 99mTc-tricine-EDDA-HYNIC-
folate with the percentage of radioactivity which was
associated with free 99mTcO4
- and 99mTcO2. The
radiochemical purity of 99mTc-tricine-EDDA-HYNIC-
folate based on the above chromatograms (Figure 5(a)
and 5(b)) and Table 1 calculated by deducting
percentage of [% 99mTc- tricine-EDDA-HYNIC-folate +
% 99mTcO2] from radiochromatogram (a) with percentage
of [99mTcO2] from radiochromatogram (b). The
radiochemical purity of 99mTc-tricine-EDDA HYNIC-
folatebased on the above-mention calculation was found
to be 95.2%. This value exceeded the radiochemical purity
required for good radiopharmaceuticals (> 90%). Several
repetitions of radiolabeling of HYNIC-folate kit with 99mTc
were successfully produced 99mTc-tricine-EDDA-HYNIC-
folatewith an average radiochemical purity of 97.0 ± 1.8%.
Based on these results, it appeared that the formulation
of Tc-HYNIC-folate kit containing tricine and EDDA
as co-ligands was suitable for preparation of 99mTc-
HYNIC-folate.
There have been a few reports regarding
the nature of formed complexes when two co-ligands
used at the same time in radiolabeling of HYNIC-BM
with 99mTc [13,14]. In case radiolabeling of HYNIC-BM
with 99mTc where tricine and TSPP used as co-ligands,
it was reported that these co-ligands were
fully participated in forming the 99mTc-tricine-
TPPTS-HYNIC-BM complex [13]. On the other
hand, radiolabeling of HYNIC-BM with 99mTc
where tricine and EDDA as co-ligands was reported
to solely form of 99mTc-EDDA-HYNIC-BM complex.
In this radiolabeling it was suggested that at the
early stage of radiolabeling 99mTc-tricine-HYNIC-BM
was formed which was followed by trans-chelation
of tricine with EDDA at a later stage of reaction [14].
The stability of 99mTc-tricine-EDDA HYNIC-
folate, measured as radiochemical purity, was observed
from radiochemical purity of 99mTc tricine-EDDAHYNIC-
folate which was stored at 37 C for up to four hours.
The radiochemical purity of 99mTc-tricine-EDDA-HYNIC-
folate was measured by TLC using ITLC-SG-acetone and
Note: (a) Developed with acetone and (b) Developed
with saline solution.
Figure 5. Radiochromatograms of 99mTc-HYNIC-folate:
(a)
(b)
Table 1. The RFs of each component resulted in radiolabeling of
99mTc-tricine-EDDA HYNIC-folate with 99mTc (Determined with
two TLC sytems)
Fig TLCSystem Rf > 0.5 Rf < 0.5
5(a) ITLC-SG/
Acetone
Free 99mTc
(2.74%)
99mTc- tricine-
EDDA-
HYNIC-folate
+ 99mTcO2
(97.26%)
5(b) ITLC-SG/
0,9% NaCl
99mTc- tricine-
EDDA
HYNIC-
folate + free
99mTc
(97.94%)
99mTcO2
(2.06%).
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ITLC-SG-saline systems. Figure 6 shows the
radiochemical purity of 99mTc-tricine-EDDA-HYNIC-
folate over four hours of observation. It can be seen on
Figure 6 that the radiochemical purity of 99mTc-tricine-
EDDA-HYNIC-folate was still high (>90%), which
indicated that 99mTc-tricine-EDDA-HYNIC-folate was still
intact after four-hours.
CONCLUSIONS
Formulation of freeze dried kit for preparation
of 99mTc-tricine-EDDA-HYNIC-folate, which consisted
of HYNIC-folate, tricine, EDDA and Sn(II) was prepared
successfully. Preparation of kits were initiated
by preparation HYNIC-folate which was prepared
by reacting folate -hydrazine with 6-chloronicotinic
acid NHS ester. The prepared HYNIC-folate was
then formulated in order to obtain HYNIC-folate kit
which consisted of HYNIC-folate, tricine and EDDA
co-ligands, and Sn(II). The radiolabeling of these kits
with 99mTc every time readily produced 99mTc-tricine-
EDDA-HYNIC-folate with radiochemical purity of 97.0 ±
1.8% which met with the requirement of a good
radiopharmaceutical. The stability test showed that the
99mTc-tricine-EDDA-HYNIC-folate was still intact
(radiochemical purity ~ 95%) when stored at 37 C for up
to four hours.
In order to use 99mTc-tricine-EDDA-HYNIC-folate
as radiodiagnostic agent for FR over expressed cancers,
further studies which include serum stability,
lipophilicity, biodistribution and clearance on normal mice
and/or xenograph, and on normal and cancer patients
need to be performed.
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Figure 6. The stability of 99mTc-tricine-EDDA HYNIC-
folate
Note: Stored at 37 °C(indicated as radiochemical purity)
